2023 / 03

Next Paper
DOI: 10.47183/mes.2023.033

ORIGINAL RESEARCH

Initial administration of β2-agonists reduces the risk of bronchospasm caused by β1-blockers in comorbid cardiorespiratory pathology

Smolyakova EV1,2, Sinitsyn EA2, Zykov KA1,2
About authors

1 Evdokimov Moscow State Medical and Biological University of the Ministry of Health of Russia, Moscow, Russia

2 Pulmonology Research Institute, Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Ekaterina V. Smolyakova
Orekhovy bulvar, 28, 115682, Moscow, Russia; ur.liam@kavokayloms

About paper

Author contribution: Smolyakova EV — recruitment of patients, processing of the results, article authoring; Sinitsyn EA — discussion of the results; Zykov KA — patient treatment management, discussion of the study results, article authoring.

Compliance with ethical standards: the study was approved by the Ethics Committee of the National Medical Research Center for Cardiology named after academician Yevgeniy Chazov of the Ministry of Health of the Russian Federation (Minutes № 220 of October 31, 2016)

Received: 2023-07-21 Accepted: 2023-09-04 Published online: 2023-09-28
|
Fig. 1. Study design. BP — blood pressure; AST — Asthma Control Test; BOD — bronchoobstructive diseases; CAT — COPD Assessment Test, mMRC — modified Medical Research Council Dyspnea Scale
Fig. 2. Distribution of patients with the greatest FEV1 drop (in % from the reference values) at different time, CVD and BOD groups
Fig. 3. Percentage of patients with CVD and BOD whose FEV1 decreased over 2% from the reference values
Table 1. Clinical characteristics of the patients with CVD and BOD, groups 1 and 2 (medical history data)
Note: the data are given as M ± SD and % of the total number of patients; * — p < 0.05; AH – arterial hypertension; ACT — asthma control test; BA — bronchial asthma; CCA — calcium channel antagonists; ARB — angiotensin-2 receptor blockers; CHD — coronary heart disease; ACE inhibitors — angiotensin converting enzyme inhibitors; mMRC — modified medical research council dyspnea scale; HA — heart arrhythmia; PICS — post-infarction cardiosclerosis; CAT — COPD assessment test; COPD — chronic obstructive pulmonary disease.
Table 2.Clinical characteristics of the patients with CVD and BOD, groups 1 and 2 (laboratory and instrumental study data)
Note: the data are given as M ± SD; * — p < 0.05; DBP — diastolic blood pressure; FEV1 — forced expiratory volume, 1 s; SBP — systolic blood pressure; ESR — erythrocyte sedimentation rate; CRP — C-reactive protein; ECP — eosinophilic cationic protein; FVC — forced vital capacity; HR — heart rate.
Table 3. Dynamics of indicators as registered with CAT, ACT, MRC questionnaires, patients with CVD and BOD comorbidities, both groups
Note: * — р < 0.05.